Showing 4721-4730 of 6808 results for "".
- Breaking Business News: ZO Skin Health, Inc. Acquires Refissa from Suneva Medicalhttps://practicaldermatology.com/news/business-news-zo-skin-health-inc-acquires-refissa-from-suneva-medical/2458298/ZO Skin Health, Inc. has acquired the worldwide rights to ReFissa as well as its generic equivalent tretinoin from Suneva Medical. Financial terms for the acquisition were not disclosed. ReFissa is the only
- New Plush Wonder Duck Toy Benefits Children's Skin Disease Foundation and Camp Wonderhttps://practicaldermatology.com/news/new-plush-wonder-duck-toy-benefits-childrens-skin-disease-foundation-and-camp-wonder/2458308/A plush version of Camp Wonder’s mascot, Wonder Duck, is now available for purchase, with 100% of the proceeds going to the Children's Skin Disease Foundation. Camp Wonder is a summer camp for children with serious and fatal skin condition
- Menlo Begins Enrollment for Phase 2 Studies of NK-1 for Pruritushttps://practicaldermatology.com/news/menlo-begins-enrollment-for-phase-2-studies-of-nk-1-for-pruritus/2458325/Menlo Therapeutics Inc. has initiated enrollment in two new Phase 2 trials evaluating a novel neurokinin 1 (NK-1) receptor antagonist, serlopitant, for the treatment of pruritus associated with atopic dermatitis and for the treatment of pruritus fol
- New Compound May Block Spread of Melanoma, Treat Sclerodermahttps://practicaldermatology.com/news/new-compound-may-block-spread-of-melanoma-treat-scleroderma/2458329/A chemical compound, and potential new drug, may reduce the spread of melanoma cells by up to 90 percent, report researchers from Michigan State University in East Lansing. The man-made, small-molecule drug compound goes after a gene’s ability to produce RNA molecules and certain pr
- AnaptysBio, Inc.'s IL-33-Blocker Cleared for Phase 2a Trials in AD, Peanut Allergyhttps://practicaldermatology.com/news/anaptysbio-incs-il-33-blocker-cleared-for-phase-2a-trials-in-ad-peanut-allergy/2458347/The United Kingdom Medicines and Healthcare Products Regulatory Agency has green lighted a Phase 2a clinical trial for AnaptysBio, Inc.’s ANB020 for the treatment of adults with moderate-to-severe atopic dermatitis. The United States Food and Drug Ad
- CDC Study: Banning Indoor Tanning Among Minors Will Save Lives, Moneyhttps://practicaldermatology.com/news/banning-indoor-tanning-among-minors-will-save-lives-money/2458354/An age restriction on indoor tanning could save thousands of lives and millions of dollars, according to new research published online in the Journal of the American Academy of Dermatology. In December 2015, the U.S. Food and Drug Administration
- Alopecia Areata Breakthrough: Two Studies Suggest JAK inhibitors May Spur Hair Regrowthhttps://practicaldermatology.com/news/alopecia-areata-breakthrough-two-studies-suggest-jak-inhibitors-may-spur-hair-regrowth/2458427/Taken together, two new studies suggest that JAK inhibitors may play a role in treating alopecia areata. Two JAK inhibitors are already approved by the U.S. FDA, XELJANZ® (tofacitinib citrate) for rheumat
- FDA Bans 19 Ingredients from Hand Soapshttps://practicaldermatology.com/news/fda-no-more-antibacterials-allowed-in-consumer-soaps/2458446/Antibacterial soaps will soon be gone from store shelves, according to a new rule from the US Food and Drug Administration (FDA). This
- Galderma and Chugai Announce Global License Agreement for Nemolizumab, Novel Biologic for Skin Diseaseshttps://practicaldermatology.com/news/galderma-and-chugai-announce-global-license-agreement-for-nemolizumab-novel-biologic-for-skin-diseases/2458496/Chugai Pharmaceutical Co., Ltd. and Galderma Pharma S.A. have entered into a global license agreement for nemolizumab (CIM331), the anti-IL-31 receptor A humanized monoclonal antibody created by Chugai, which is currently under development for atopic dermatitis and pruritus in hemodialysis patien
- New Psoriasis Drug Taltz Shows Benefit Through 60 Weekshttps://practicaldermatology.com/news/new-psoriasis-drug-taltz-shows-benefit-through-60-weeks/2458536/Three new studies demonstrate the efficacy and safety of Eli Lilly's Taltz® (ixekizumab) through 60 weeks among patients with moderate-to-severe plaque psoriasis. The findings appear in the